Response to Treatment Series: Part 2, tumor response assessment - Using new and conventional criteria

Vahid Yaghmai*, Frank H Miller, Pedram Rezai, Al B Benson III, Riad Salem

*Corresponding author for this work

Research output: Contribution to journalComment/debate

43 Scopus citations

Abstract

OBJECTIVE. Conventional anatomic imaging biomarkers, including World Health Organization (WHO) criteria and Response Evaluation Criteria in Solid Tumors (RECIST), although effective, have limitations. This article will discuss the conventional and newer morphologic imaging biomarkers for the assessment of tumor response to therapy. CONCLUSION. Applying established methods of assessing tumor response to therapy allows consistency in image interpretation and facilitates communication with oncologists. Because of the new methods of treatment, assessment of necrosis and volumetric information will need to be incorporated into size-based criteria.

Original languageEnglish (US)
Pages (from-to)18-27
Number of pages10
JournalAmerican Journal of Roentgenology
Volume197
Issue number1
DOIs
StatePublished - Jul 1 2011

Keywords

  • Choi criteria
  • EASL
  • Imaging biomarkers
  • Oncologic imaging
  • RECICL
  • RECIST
  • Tumor response

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Response to Treatment Series: Part 2, tumor response assessment - Using new and conventional criteria'. Together they form a unique fingerprint.

  • Cite this